In recent years, the research and development of antibody-drug conjugates (ADCs) has continued to heat up, with collaborations, licensing, and mergers and acquisitions in the field being active. Based on the design concept of ADC drugs and the development of bioconjugation technology, more conjugated drug candidates (XDCs) designed based on 'target molecule + conjugate drug' are rapidly following suit in R&D, including peptide conjugate drugs (PDCs), radionuclide conjugate drugs (RDCs), small molecule conjugate drugs (SMDCs), etc. XDC drugs are expected to usher in a new era of targeted therapy. The research and development of XDC drugs is booming globally. As of September 2023, there are already 354 XDC drugs in clinical trials or application for marketing worldwide.
Following the industry development hotspots, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') is preparing to publish the 'Blue Book on the Current Situation and Development Trends of the XDC Drug Industry'. The aim is to conduct an in-depth analysis of the XDC drug sector, providing a multi-dimensional and comprehensive description of its structure, mechanism of action, marketed drugs, research pipelines, market size, capital enthusiasm, etc. It tracks the development context of industries and technologies, explores the huge potential for industry development, and analyzes the driving factors behind market development.
The Life Sciences Practice of Frost & Sullivan is pleased to invite XDC pharmaceutical companies to participate in the Blue Book to jointly discuss the development direction and prospects of the XDC pharmaceutical field.
The Frost & Sullivan Life Sciences Practice will hold an online launch event for the 'Blue Book on the Current Situation and Development Trends of the Pharmaceutical Industry' in late November, which will be pushed simultaneously through the Frost & Sullivan WeChat official account and multiple media platforms. Stay tuned!
1
Research content
1) From ADCs to XDCs, technological progress has driven the development of various drugs, expanding their indications. Conjugated drugs are extending beyond ADC formats. This review covers ADCs, RDCs,PDCMechanism of action, clinical advantages, and development history of SMDC;
2) A total of 15 ADC drugs have been approved for marketing globally, analyze ADCs,RDCInsights into the current industry development status and competitive landscape, including marketed products, research pipelines, and difficulties in R&D and production processes corresponding to PDC, SMDC drugs;
(3) The global ADC drug market size reached $7.9 billion in 2022. With the advancement of clinical pipelines and acceleration of commercialization, it is expected that the global ADC drug market size will reach $64.7 billion by 2030. The XDC drug market has broad prospects, and this analysis includes an assessment of the market size, market drivers, and industry development trends.
4) In recent years, several multinational companies have actively positioned themselves in the XDC space through mergers and acquisitions, cooperative development, and licensing. The overall amount of financing in the primary market for XDC drugs has been on the rise. Analyze the capital market performance of XDC drugs;
5) There are already multiple companies competing on the XDC track, and technological innovation and the expansion of indications will become the core driving forces for competitors. This presentation will cover the business layout, pipeline deployment, technology platforms, and technological breakthroughs of the major enterprises in the XDC field.
2
Participation value
1) The 'Blue Book on the Current Situation and Development Trends of the Pharmaceutical Industry in China' will be released online simultaneously through the official Frost & Sullivan account and multiple media platforms, highlighting the differentiated characteristics of enterprises and enhancing their visibility in the capital market;
2) Cover hundreds of millions of customers, seamlessly integrating media, funds, banking, and brokerage communication channels. With over 5,000 high-quality media resources, effective deployment and promotion strategies can be carried out with precise placement;
3) Based on a mature industry analysis model, covering the core elements of market analysis, presenting a comprehensive and in-depth understanding of the industry, disseminating new concepts, and jointly exploring value enhancement paths with XDC pharmaceutical companies;
4) Share industry insights and deepen corporate image through online or offline activities such as roundtable discussions, themed salons, and video live broadcasts in related fields organized by Frost & Sullivan.
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating extensive project experience across various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingProjects (DCF valuation, business plan services), IPO listing projects (industry advisory, clinical audit, fundraising and investment writing), market research, market value management and strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices, attracting widespread attention from investors.
2023 Frost & Sullivan New Investment Conference
